Precision BioSciences, Inc. presented preclinical data at the Global Hepatitis Summit (GHS) 2025 on March 20, 2025, supporting repeat dosing of PBGENE-HBV in the ELIMINATE-B trial for chronic HBV.
The data highlighted the potential to safely administer repeated doses of PBGENE-HBV, a lipid nanoparticle (LNP) delivered gene editor, to achieve durable functional cures. In non-human primates, repeated administration was safe and well tolerated, with no systemic accumulation or risk of heritable genome edits.
The company previously showed that two doses of PBGENE-HBV achieved up to 99% viral eradication in non-human primates. This compelling data supports the ELIMINATE-B Phase 1 clinical trial design, which evaluates up to three dose administrations per patient at each dose level to assess the cumulative effect of editing and eliminating viral DNA.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.